![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Bone Study Shows ImpediMed's SOZO Measures Cancer Patients’ Bone Mineral Content
Bone Study Shows ImpediMed's SOZO Measures Cancer Patients’ Bone Mineral Content
ImpediMed’s SOZO digital health platform achieved results comparable to dual x-ray absorptiometry in assessing bone mineral content in cancer patients, the company reported at the 39th Annual Miami Breast Cancer Conference, March 3-6.
SOZO is a noninvasive bioimpedance spectroscopy device that provides a snapshot of fluid status and tissue composition in less than 30 seconds.
The study demonstrated a strong correlation between skeletal muscle mass data collected using SOZO and bone mineral content (BMC) data collected using dual x-ray absorptiometry in healthy subjects, cancer patients during treatment and cancer patients after treatment.
Multiple studies have shown a strong a correlation between skeletal muscle mass and bone “suggesting that a SOZO reading can provide a simple, quick and reproducible estimate of BMC,” the company said.
Upcoming Events
-
18Jul
-
21Oct